Last reviewed · How we verify
placebo + Rosuvastatin
placebo + Rosuvastatin is a HMG-CoA reductase inhibitor Small molecule drug developed by Jeil Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Hypercholesterolemia, Prevention of cardiovascular disease.
Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway.
Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. Used for Hypercholesterolemia, Prevention of cardiovascular disease.
At a glance
| Generic name | placebo + Rosuvastatin |
|---|---|
| Sponsor | Jeil Pharmaceutical Co., Ltd. |
| Drug class | HMG-CoA reductase inhibitor |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting HMG-CoA reductase, Rosuvastatin reduces the liver's production of cholesterol, thereby lowering LDL cholesterol levels in the blood. This is particularly beneficial for patients with hypercholesterolemia or at risk of cardiovascular disease.
Approved indications
- Hypercholesterolemia
- Prevention of cardiovascular disease
Common side effects
- Muscle pain
- Liver enzyme elevation
- Diarrhea
Key clinical trials
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine (PHASE4)
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (PHASE3)
- A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia (PHASE2, PHASE3)
- A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (PHASE1)
- Investigation of the Gut Microbiome and Statin Response (PHASE4)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (PHASE3)
- Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo + Rosuvastatin CI brief — competitive landscape report
- placebo + Rosuvastatin updates RSS · CI watch RSS
- Jeil Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about placebo + Rosuvastatin
What is placebo + Rosuvastatin?
How does placebo + Rosuvastatin work?
What is placebo + Rosuvastatin used for?
Who makes placebo + Rosuvastatin?
What drug class is placebo + Rosuvastatin in?
What development phase is placebo + Rosuvastatin in?
What are the side effects of placebo + Rosuvastatin?
What does placebo + Rosuvastatin target?
Related
- Drug class: All HMG-CoA reductase inhibitor drugs
- Target: All drugs targeting HMG-CoA reductase
- Manufacturer: Jeil Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypercholesterolemia
- Indication: Drugs for Prevention of cardiovascular disease
- Compare: placebo + Rosuvastatin vs similar drugs
- Pricing: placebo + Rosuvastatin cost, discount & access